- Home
- CLLS vs PDCC Comparison
CLLS vs PDCC Comparison
Compare CLLS & PDCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- PDCC
- Stock Information
- Founded
- CLLS 1999
- PDCC N/A
- Country
- CLLS France
- PDCC
- Employees
- CLLS N/A
- PDCC N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- PDCC
- Sector
- CLLS Health Care
- PDCC
- Exchange
- CLLS Nasdaq
- PDCC NYSE
- Market Cap
- CLLS 143.4M
- PDCC 123.0M
- IPO Year
- CLLS 2007
- PDCC N/A
- Fundamental
- Price
- CLLS $1.59
- PDCC $17.85
- Analyst Decision
- CLLS Buy
- PDCC
- Analyst Count
- CLLS 1
- PDCC 0
- Target Price
- CLLS $4.00
- PDCC N/A
- AVG Volume (30 Days)
- CLLS 48.2K
- PDCC N/A
- Earning Date
- CLLS 08-05-2025
- PDCC N/A
- Dividend Yield
- CLLS N/A
- PDCC N/A
- EPS Growth
- CLLS N/A
- PDCC N/A
- EPS
- CLLS N/A
- PDCC N/A
- Revenue
- CLLS $54,747,000.00
- PDCC N/A
- Revenue This Year
- CLLS $48.52
- PDCC N/A
- Revenue Next Year
- CLLS $5.17
- PDCC N/A
- P/E Ratio
- CLLS N/A
- PDCC N/A
- Revenue Growth
- CLLS 351.26
- PDCC N/A
- 52 Week Low
- CLLS $1.10
- PDCC N/A
- 52 Week High
- CLLS $2.43
- PDCC N/A
- Technical
- Relative Strength Index (RSI)
- CLLS 56.98
- PDCC N/A
- Support Level
- CLLS $1.56
- PDCC N/A
- Resistance Level
- CLLS $1.49
- PDCC N/A
- Average True Range (ATR)
- CLLS 0.09
- PDCC 0.00
- MACD
- CLLS 0.01
- PDCC 0.00
- Stochastic Oscillator
- CLLS 80.00
- PDCC 0.00
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About PDCC PEARL DIVER CREDIT COMPANY INC
PEARL DIVER CREDIT COMPANY INC is an externally managed, non-diversified, closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation by investing predominantly in third-party Collateralized Loan Obligation (CLO) equity and mezzanine tranches of predominately U.S.-dollar-denominated CLOs backed by corporate leveraged loans issued mainly to U.S. obligors.